MedTrace Logo

Pharmacokinetics Study for Probucol

NCT01000467 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-03-04

No results posted yet for this study

Summary

To evaluate the safety and pharmacokinetics of probucol by multiple oral administration in healthy male subjects.

Conditions

  • Healthy

Interventions

DRUG

probucol

group 3: 250 mg 1 tablet in the morning and evening

DRUG

probucol

group 1: 250 mg

DRUG

probucol

group 2: 250 mg 2 tablets at once in the morning

Sponsors & Collaborators

  • Korea Otsuka Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Kyung-Sang Yoo, MD, PhD · Clinical Trial Center, Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2009-08-31
Completion
2009-09-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01000467 on ClinicalTrials.gov